NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
0.9081
-0.1019 (-10.09%)
At close: Nov 5, 2026, 4:00 PM EST
0.9490
+0.0409 (4.50%)
After-hours: Nov 5, 2026, 7:30 PM EST
NovaBridge Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
30
Market Cap
105.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 632.00K | 2.18M | - |
| Dec 31, 2022 | -1.55M | -15.40M | - |
| Dec 31, 2021 | 13.85M | -222.30M | -94.14% |
| Dec 31, 2020 | 236.15M | 231.84M | 5,381.18% |
| Dec 31, 2019 | 4.31M | -3.51M | -44.90% |
| Dec 31, 2018 | 7.82M | 6.04M | 340.20% |
| Dec 31, 2017 | 1.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Foghorn Therapeutics | 36.74M |
| Voyager Therapeutics | 34.46M |
| Armata Pharmaceuticals | 5.54M |
| Equillium | 4.39M |
| Humacyte | 2.12M |
| Outlook Therapeutics | -1.16M |
NBP News
- 3 days ago - NovaBridge Biosciences Transcript: KOL event - Transcripts
- 3 days ago - NovaBridge Biosciences Press release: KOL event - Filings
- 3 days ago - NovaBridge Biosciences Slides: KOL event - Filings
- 8 days ago - NovaBridge appoints Chuck Silberstein as CFO - TheFly
- 8 days ago - NovaBridge Biosciences Appoints Chuck Silberstein as Chief Financial Officer - GlobeNewsWire
- 11 days ago - NovaBridge announces presentation of results from Phase 1b study of givastomig - TheFly
- 11 days ago - NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development - GlobeNewsWire
- 16 days ago - Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia - GlobeNewsWire